The RIGHT Choice, a randomized, phase II, open-label, multicenter clinical trial presented at the 2022 San Antonio Breast Cancer Symposium (SABCS), offered the first head-to-head comparison of CDK4/6i plus ET versus CT in advanced HR + /HER2- breast cancer with life-threatening VC. The gene discussed is CDK4; the disease is breast carcinoma.